

Division of Pediatric Hematology and Oncology

*Saint Louis University School of Medicine
at SSM Health Cardinal Glennon
Children's Hospital, St. Louis, MO*



The SLUCare Division of Pediatric Hematology and Oncology is ranked among the best in the country for its comprehensive and multidisciplinary approach toward the diagnosis and treatment of childhood cancers and blood disorders.

The hospital has a large, dedicated outpatient oncology center that offers chemotherapy, transfusions and other drug treatments in close proximity to multidisciplinary oncology clinics, which include specialists in oncology/hematology, pediatric surgery, neurosurgery, orthopedic surgery, radiation oncology and clinical pathology. A recently expanded and renovated inpatient oncology unit and a dedicated stem cell and bone marrow unit both have all private rooms to optimize the care of patients and minimize the risk of infection.

CAR T Cell and Precision Cancer Therapies

A hallmark of the oncology program is the use of advanced genomic profiling to customize precision oncology treatment plans and improve survival outcomes of pediatric cancer patients. The hospital is part of the multicenter Beat Childhood Cancer Research Consortium which has conducted multiple trials using genomic profiling to identify targeted therapies for relapsed and high-risk malignancies, and more recently has applied this technology to advancing the treatment for children with high risk neuroblastoma.

One of the newest advanced treatments now available is CAR T cell therapy for the treatment of relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL). SSM Health Cardinal Glennon Children's Hospital is among only 62 pediatric centers in the country currently offering the FDA-approved treatment for children up to age 25.

Sickle Cell Disease Treatment and Research Center

SSM Health Cardinal Glennon Children's Hospital is a federally designated Sickle Cell Disease Treatment and Research Center for both Missouri and Illinois. The center treats a variety of sickle cell diseases, including less common compound forms such as HbSD, HbSO and HbSE. Treatment options include blood transfusions, chelation therapy, hydroxyurea, and stem cell transplantation. The center also is actively offering and evaluating three drugs recently approved by the FDA for the treatment of sickle cell disease: L-glutamine (age 5+), crizanlizumab-tmca (age 16+), and voxelotor.


The center is part of the multi-center DISPLACE study, evaluating barriers to stroke screening and prevention in children diagnosed with sickle cell disease. Phase III of the study focuses on the use of Transcranial Doppler (TCD) ultrasound to identify young patients at risk for stroke. Adherence to regular TCD screenings is deemed important and SSM Health Cardinal Glennon offers these screenings annually from age 2 through age 16, with monthly transfusions recommended for any patient with abnormal TCD findings.



Blood and Bone Marrow Transplant Program

The Blood and Bone Marrow Transplant Program has documented superb patient care and survival outcomes for almost 20 years. One-year transplant survival rates have consistently exceeded national averages for all US transplant centers.

One-Year Overall Survival by Year



Neuro-Oncology Program

A multidisciplinary neuro-oncology program focuses on the treatment of children diagnosed with new or recurrent brain tumors and other nerve-tissue cancers, including neurofibromatosis and neuroblastoma. The program includes a variety of pediatric subspecialists working in a multidisciplinary clinic setting that includes neurosurgeons, neuro-oncologists, neuro-radiologists and radiation oncologists, and neuro-pathologists as well as specialists in endocrinology, psychology, palliative care, physical and occupational therapy, and social work.

Through the Neurofibromatosis and Tuberous Sclerosis Complex clinics, specialists also have several clinical trials under way for novel treatments.

For children diagnosed with brain tumors, the use of oral targeted chemotherapy agents that can be given conveniently at home has reduced hospital stays and outpatient clinic infusion visits to almost zero.



Bone and Soft Tissue Sarcomas

SSM Health Cardinal Glennon Children's Hospital's bone and soft tissue sarcoma program is recognized for excellent functional outcomes and limb preservation. The team is active participants in collaborative research consortiums that have identified advanced treatment options for osteosarcoma and Ewing's sarcoma and improved survival outcomes. In addition to pediatric oncologists, the team includes pediatric orthopedic surgeons and radiation oncologists.

Hemostasis Program

The Comprehensive Hemophilia Treatment Center at SSM Health Cardinal Glennon Children's Hospital is the oldest federally designated pediatric center of its kind in the region and has documented long-standing excellent outcomes above regional and national benchmarks for young patients referred to the program.

The center offers numerous clinical trials evaluating effective treatment options for hemophilia and other bleeding or clotting disorders. Among the options is the use of emicizumab for the treatment of hemophilia A. The medication is now in clinical trials (ATHN7 Trial) at SSM Health Cardinal Glennon to monitor its safety in children with hemophilia A. To date, 75% of severe hemophilia patients seen in the center are on emicizumab, which is more convenient to administer and has demonstrated a significant reduction in abnormal bleeding events. A commentary by SLUCare hematologist/oncologist John Puetz, MD, accepted by the Journal of Thrombosis and Haemostasis, focuses on the importance of more investigation into the additive effects between emicizumab and factor VIII. Early studies show that lower doses of factor VIII appear to have an additive effect with emicizumab. Patients with hemophilia A receiving

emicizumab may benefit from lower doses of factor VIII when treating abnormal bleeding.

In addition to hemophilia, the program also treats children with thrombotic events (blood clots, DVT, PE, stroke). More than 50 newly diagnosed infants and children are seen annually for risk assessment or treatment of thrombotic events. Hematology specialists here are members of the International Pediatric Thrombosis Network.

Innovative Oncology Clinical Research

SSM Health Cardinal Glennon Children's Hospital is a founding member of the Beat Childhood Cancer Consortium. It also is active in the Children's Oncology Group, the Pediatric Blood and Marrow Transplant Consortium, the Center for International Blood and Marrow Research, and the Primary Immunodeficiency Treatment Consortium. These multicenter collaborative efforts offer opportunities to participate in and offer the most novel oncology therapeutics under evaluation at any given time.


Late Effects Program

A multidisciplinary team offers specialized care for survivors of childhood cancer and those who have undergone blood or bone marrow transplants. Studies have found that 60% or more of young cancer survivors can develop chronic health problems or complications as they age into adulthood. The Late Effects Program is designed to offer coordinated management and transitional care to address these long-term needs.

Hematology and Oncology Fellowship

Saint Louis University School of Medicine offers an accredited three-year fellowship in pediatric hematology and oncology at SSM Health Cardinal Glennon Children's Hospital.

Hemophilia Treatment Center Quality Metrics



For physician consultations, contact the SSM Health Cardinal Glennon Access Center at **1-888-229-2424**.

SLUCare Division of **Pediatric Hematology** and **Oncology Faculty**



William Ferguson, MD

Director, Division of Pediatric Hematology and Oncology

Professor of Pediatrics

Saint Louis University School of Medicine

Deepika Bhatta, MD

Leili Dolatshahi, MD

John Dombrowski, MD

Lauren Draper, MD

David Greenberg, MD

Christopher Hugge, MD

Pournima Navalkele, MD

John Puetz, MD

Shermini Saini, MD

Lauren Delashmit, RN, MSN, CPNP

Robert Parker, RN, MSN, CPNP

Abigail Sharamitaro, RN, MSN, CPNP, CPON

For physician consultations or referrals, call the SSM Health Cardinal Glennon Access Center at **1-888-229-2424**.

Pediatric hematologists and oncologists at SSM Health Cardinal Glennon Children's Hospital are faculty of Saint Louis University School of Medicine and members of its SLUCare Physician Group. The hospital is the only free-standing, not-for-profit Catholic pediatric hospital in the United States. It is a member of SSM Health, one of the largest Catholic health care systems in the country and is affiliated with Saint Louis University School of Medicine. For more information about the hospital, visit cardinalglennon.com.



1465 S. Grand Boulevard | St. Louis, MO 63104